All these studies above suggest that antibody-trap like IMM0306 might be an ideal approach for CD47-targeted immunotherapy development since selective avoidance of RBCs mediated antigen-sink as well as anemia could be achieved along with the robust anti-tumor activity. This evidence concerns the gene CD47 and anemia.